HOPPR vs MEDICAL IP (2026)
Two companies whose products end up inside other people's imaging AI. HOPPR sells a multimodal foundation model and a development environment for building imaging applications, with detailed model and technology disclosure, which matters when others build regulated products on its weights. MEDICAL IP sells segmentation and quantification, one capability underneath a broad portfolio, with one of the widest multi jurisdiction regulatory footprints here and genuinely strong published validation. Neither is bought by a radiologist. Both carry the same unaddressed risk: bias at this layer propagates into every downstream product and the eventual buyer never sees where it came from, and neither publishes a subgroup analysis.
- It is infrastructure for building imaging AI rather than a clinical application, with a multimodal foundation model and a development environment sold to developers and imaging vendors.
- It discloses its model and technology in detail, which matters because other companies build regulated products on top of it.
- The consent basis for training data is stated rather than implied, which almost nothing in this lane does.
- Segmentation and quantification is one capability underneath a whole portfolio, evidenced rather than claimed across modalities and body regions.
- Its approvals span several jurisdictions, with FDA clearance for MEDIP PRO and DeepCatch, Korean approvals up to Class III, CE marking, UK MHRA registration and a Chinese NMPA certificate.
- DeepFore, its liver cancer prediction model, was published in the Journal of Hepatology in 2025.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. HOPPR and MEDICAL IP are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | HOPPR | MEDICAL IP |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2019 | 2015 |
| Headquarters | Chicago, Illinois | Seoul, South Korea |
| Website | hoppr.ai | medicalip.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
HOPPR
-
Model / architecture
HOPPR released a beta of its FS MSK Narrative Model for whole body X-rays, a vision language foundation model that drafts the findings section of a musculoskeletal X-ray report from up to three views.
Source -
Model / architecture
HOPPR expanded its vision-language model portfolio with the release of a new 2D Mammography Narrative Model.
Source
MEDICAL IP
-
Clinical evidence
A retrospective study published in PLOS ONE validated MEDIP PRO's ability to segment orbital structures on CT imaging to assess Thyroid Eye Disease (TED) activity.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
HOPPR builds infrastructure for making medical imaging AI and, separately, a layer that delivers AI results into radiology reporting. Grace is a multimodal imaging foundation model for X-ray, CT, MRI and echocardiography, trained on more than a petabyte of permission based, anonymized studies paired with reports; narrative models translate chest radiographs (April 2026) and 2D mammograms (August 2026) into structured text and ship with training data traceability records and version locking.
Source: AI Health Index, August 2026
MEDICAL IP builds AI segmentation and quantification software for medical imaging. MEDIP PRO converts CT and MRI into segmented 3D anatomical models for planning and 3D printing; DeepCatch measures muscle, visceral fat and bone density on CT, and the DeepCatch X modules take measurements from a single chest X-ray (aorta, heart, torso, tuberculosis and emphysema); DeepFore predicts liver cancer occurrence and DeepFore Recur its recurrence; TiSepX performs lung volumetry.
Source: AI Health Index, August 2026
Questions buyers ask
How are HOPPR and MEDICAL IP priced and sold?
For HOPPR, the Foundry is sold as platform access to developers, AI companies and imaging software vendors through an access request, with Forward Deployed Services as a separate professional services engagement, and Presto Agent is sold separately to radiology practices.
With MEDICAL IP, the portfolio makes the gap wider: MEDIP PRO, the individual DeepCatch X modules, DeepFore, the ANATDEL 3D printing service and the anatomy education products are different propositions with different natural units, and nothing indicates whether they are licensed separately or bundled, or priced per study, per seat or per site. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Radiology & Imaging AI page.
These sit at different layers and are compared because both are inputs to other people's clinical products rather than end user applications. Neither publishes a bias or subgroup analysis, which propagates differently at this layer: a segmentation model that performs unevenly across body habitus or a foundation model trained on an unrepresentative corpus carries that variation into every downstream product built on it, and the downstream buyer will never see it. Neither publishes pricing, and MEDICAL IP publishes no data handling or residency terms.